Publications by authors named "Alexander Starodub"

Claim this Profile
P
Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
Rahul Aggarwal, Alexander N Starodub, Brian D Koh, Guan Xing, Andrew J Armstrong

Clin Cancer Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Alexander Starodub

J Immunother Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer.
Jonathan W Goldman, Minal Barve, Jyoti D Patel, Antoinette Wozniak, Afshin Dowlati, Alexander Starodub

Clin Transl Sci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).
Manish A Shah, Gyorgy Bodoky, Alexander Starodub, David Cunningham, Desmond Yip

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Johanna Bendell, Sunil Sharma, Manish R Patel, Kevin S Windsor, Zev A Wainberg, Alexander Starodub

Oncologist· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Kimmie Ng, Andrew Hendifar, Alexander Starodub, Jorge Chaves, Yingsi Yang

Invest New Drugs· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study.
Manish A Shah, Alexander Starodub, Sunil Sharma, Jordan Berlin, Manish Patel

Clin Cancer Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.
Matthew D Galsky, Huan Wang, Noah M Hahn, Przemyslaw Twardowski, Sumanta K Pal, Alexander Starodub

Eur Urol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Allyson J Ocean, Alexander N Starodub, Aditya Bardia, Linda T Vahdat, Steven J Isakoff

Cancer· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
Jhanelle E Gray, Rebecca S Heist, Alexander N Starodub, D Ross Camidge, Ebenezer A Kio

Clin Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.
Efrat Dotan, Steven J Cohen, Alexander N Starodub, Christopher H Lieu, Wells A Messersmith

J Clin Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
Rebecca Suk Heist, Michael J Guarino, Gregory Masters, W Thomas Purcell, Alexander N Starodub

J Clin Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A Mayer, Jennifer R Diamond, Rebecca L Moroose, Steven J Isakoff, Alexander N Starodub

J Clin Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
Alexander N Starodub, Allyson J Ocean, Manish A Shah, Michael J Guarino, Vincent J Picozzi

Clin Cancer Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Vincent J Picozzi, Ramesh K Ramanathan, Maeve A Lowery, Allyson J Ocean, Edith P Mitchel, Alexander N Starodub

Eur J Cancer· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.
Sumanta Pal, Arun Azad, Shailender Bhatia, Harry Drabkin, Brian Costello, Alexander Starodub

Clin Cancer Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Fatima Rangwala, Johanna C Bendell, Mark F Kozloff, Christy C Arrowood, Andrew Dellinger, Alexander N Starodub

Invest New Drugs· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
John H Strickler, Shannon McCall, Andrew B Nixon, John C Brady, Herbert Pang, Alexander Starodub

Invest New Drugs· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
John H Strickler, Alexander N Starodub, Jingquan Jia, Kellen L Meadows, Andrew B Nixon

Cancer Chemother Pharmacol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.
Gordana Vlahovic, Kellen L Meadows, Hope E Uronis, Michael A Morse, Gerard C Blobe, Alexander N Starodub

Cancer Chemother Pharmacol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current immunotherapeutic strategies in colon cancer.
Michael Morse, Lee Langer, Alexander Starodub, Amy Hobeika, Timothy Clay

Surg Oncol Clin N Am· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis